← Issue №12/ week of Sep 20, 2026/ the whole section, in full

IBD, in full.

All 6 IBD papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 6, in full

most clinically useful first
IBD prospective cohort · n=100 · Sep 18, 2026 · BMC Gastro · IF 2.5

Leucine-rich alpha-2 glycoprotein as a predictor of primary non-response to anti-TNF-α therapy in biologic-naïve Egyptian IBD patients.

Diagnosticbiologicsanti-TNFbiomarkerCrohn's disease
Clinical takeawayConsider measuring baseline serum LRG in biologic-naïve Egyptian IBD patients to estimate moderate-risk (not definitive) of primary non-response to anti-TNF-α therapy. Patients with LRG >29 µg/mL may benefit from alternative therapeutic strategies.
What it foundBaseline serum LRG >29 µg/mL predicted primary non-response to anti-TNF-α therapy (adalimumab or infliximab) vs response, with sensitivities of 74.2% (UC) and 80.0% (CD) and specificities of 69.57% (UC) and 65.71% (CD) in biologic-naïve Egyptian IBD patients.
ContextThis study introduces LRG as a predictive biomarker with moderate discriminatory ability for anti-TNF-α response in Egyptian patients, addressing a gap in current practice where primary non-response remains a significant challenge.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

Decision at stakepredicting primary non-response to anti-TNF therapy in ulcerative colitis

… After anti-TNF primary non-response, switch mechanism rather than cycling within the class. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Amer I … El Sharawy S · BMC Gastroenterology · IF 2.5 · PubMed ↗Permalink
IBD retrospective · n=315 · Sep 18, 2026 · Dig Dis Sci · IF 2.5

Frequent Use of Restricted Oral Intake During Hospitalization for IBD Flares Was Not Associated with Improved Clinical Outcomes: A Multicenter Retrospective Cohort Study.

New evidenceCrohn's diseaseulcerative colitisbiologics
Clinical takeawayAvoid routine NPO or clear liquid diets in IBD flare hospitalizations without obstruction, abscess, or fistula, as they do not improve outcomes.
What it found90.1% of hospitalized IBD flare patients had restricted oral intake (NPO or clear liquids) for 35.4% of stay, with no difference in 30/90-day readmission, unplanned surgery, or biologic use across quartiles of restriction duration.
ContextChallenges common but unproven practice; aligns with guidelines against routine dietary restriction in uncomplicated IBD flares.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

Decision at stakeavoiding routine dietary restriction in hospitalized IBD flare patients without obstruction, abscess, or fistula

… Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Phan V … Feagins LA · Digestive Diseases and Sciences · IF 2.5 · PubMed ↗Permalink
IBD meta analysis · n=6,753 · Sep 18, 2026 · Clin Gastro Hep · IF 16.2

Vedolizumab trough concentrations and clinical and endoscopic outcomes in inflammatory bowel disease: a systematic review and meta-analysis.

New evidenceulcerative colitisCrohn's diseasebiologicstherapeutic drug monitoring
Clinical takeawayHigher vedolizumab trough concentrations are associated with remission, but prospective trials are needed before considering proactive therapeutic drug monitoring in UC and CD.
What it foundHigher vedolizumab trough concentrations were associated with endoscopic remission in UC (mean difference 4.86 μg/mL, 95% CI 2.75-6.98) and clinical remission in both UC (3.18 μg/mL) and CD (3.08 μg/mL), but not endoscopic remission in CD (1.40 μg/mL, p=0.453).
ContextConfirms and quantifies prior observational data on vedolizumab TDM, but highlights uncertainty due to cross-sectional design and lack of CD endoscopic association. The cross-sectional nature limits causal inference.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Soliman MA … Papamichael K · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBD prospective cohort · n=10,229 · Sep 16, 2026 · Clin Gastro Hep · IF 16.2

Integrated metabolomic and genetic profiling implicate loss of docosahexaenoic acid in the link between ultra-processed foods and Crohn's disease.

Basic scienceCrohn's diseasebasic sciencebiomarkerepidemiology
Clinical takeawayNo clinical action yet: a mechanistic finding linking DHA depletion to Crohn's disease risk in observational cohorts.
What it foundLower circulating docosahexaenoic acid (DHA) mediates 17.1% of the association between ultra-processed food intake and Crohn's disease risk (HRper SD=2.65, 95% CI 1.57-4.48).
ContextThis study identifies a potential metabolic pathway (DHA depletion) linking ultra-processed food intake to Crohn's disease risk, opening a question for future intervention trials.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakethe role of dietary factors like ultra-processed foods in Crohn's disease risk

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Wang S … Chen J · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBD review · Sep 18, 2026 · Nat Rev Gastro Hep · IF 57.5

The exposome and inflammatory bowel disease: a framework for primary and primordial prevention.

Basic science
Clinical takeawayNo clinical action yet: a mechanistic framework for understanding environmental contributions to IBD risk, without specific interventions tested in humans.
What it foundThe exposome framework emphasizes actionable environmental factors (e.g., food contact contaminants, microplastics) for IBD prevention, differentiating primary (at-risk individuals) and primordial (general population) strategies.
ContextRefines current understanding of IBD etiology by integrating environmental exposures, but lacks direct evidence for clinical interventions.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

Decision at stakethe role of environmental factors in IBD prevention and risk mitigation

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Agrawal M … Colombel JF · Nature Reviews Gastroenterology & Hepatology · IF 57.5 · PubMed ↗Permalink
IBD review · Sep 14, 2026 · Nat Rev Gastro Hep · IF 57.5

Drug-microbiome-host interactions: antimicrobial effects of non-antibiotic compounds.

Basic sciencemicrobiomebasic sciencetranslational
Clinical takeawayNo clinical action yet: a mechanistic review of non-antibiotic compounds' effects on the microbiome.
What it foundNon-antibiotic compounds often exert stronger effects on beneficial bacteria than on Enterobacteriaceae, potentially disrupting microbiome balance.
ContextChallenges the traditional view of antimicrobials by highlighting broader impacts of non-antibiotic compounds on microbiome health.
Emergingsuggested applicable standard· American College of Gastroenterology (Kelly CR, Fischer M, Allegretti JR, et al.), "ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections," American Journal of Gastroenterology, 2021

Decision at stakeunderstanding the broader antimicrobial effects of non-antibiotic compounds on the microbiome

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

DIAGNOSIS. Test only individuals with symptoms suggestive of active CDI, defined as ≥3 unformed stools in 24 hours (key concept); testing of formed stool is rarely clinically indicated, and routine testing for cure in asymptomatic patients after treatment is not recommended. CDI testing algorithms should include both a highly sensitive and a highly specific testing modality to distinguish colonization from active infection (conditional, low quality); ACG's stated preferred method is a two-step algorithm, a highly sensitive NAAT or GDH first, then the more specific toxin EIA. Both positive = CDI reliably diagnosed; both negative = CDI unlikely; discordant (NAAT/GDH positive, toxin EIA negative) requires clinical evaluation and consideration of colonization or toxin below the limit of detection. Because no test is perfect, the diagnosis and decision to treat is a clinical one, and treatment should not be withheld where clinical suspicion is high. INITIAL NONSEVERE EPISODE. Either oral vancomycin 125 mg four times daily for 10 days (strong recommendation, low quality) OR oral fidaxomicin 200 mg twice daily for 10 days (strong recommendation, moderate quality), one agent as monotherapy, not the two given together, as co-equal first-line strong recommendations; ACG does not rank fidaxomicin above vancomycin. Oral metronidazole 500 mg three times daily for 10 days may be considered in low-risk patients, i.e. younger patients with minimal comorbidities (strong recommendation, moderate quality). SEVERE CDI. As initial therapy, vancomycin 125 mg four times daily for 10 days (strong recommendation, low quality); fidaxomicin 200 mg twice daily for 10 days carries only a conditional recommendation, very low quality. FULMINANT CDI. Medical therapy including adequate volume resuscitation plus oral vancomycin 500 mg every 6 hours for the first 48-72 hours (strong recommendation, very low quality); combination therapy with parenteral metronidazole 500 mg every 8 hours can be considered (conditional, very low quality); in patients with an ileus, the addition of vancomycin enemas 500 mg every 6 hours may be beneficial (conditional, very low quality). FMT is suggested for severe and fulminant CDI refractory to antibiotic therapy, particularly in poor surgical candidates (strong recommendation, low quality). Where surgery is required, either total colectomy with end ileostomy and stapled rectal stump or diverting loop ileostomy with colonic lavage and intraluminal vancomycin, depending on clinical circumstances and the surgeon's judgement. FIRST RECURRENCE. Tapering/pulsed-dose vancomycin for patients experiencing a first recurrence after an initial course of fidaxomicin, vancomycin, or metronidazole (strong recommendation, very low quality); fidaxomicin is recommended for a first recurrence after an initial course of vancomycin or metronidazole (conditional recommendation, moderate quality). ACG's strong recommendation here is the vancomycin taper, not fidaxomicin. SECOND OR FURTHER RECURRENCE. Treat with FMT to prevent further recurrences (strong recommendation, moderate quality), delivered by colonoscopy (strong, moderate) or capsules (strong, moderate), with delivery by enema suggested only if other methods are unavailable (conditional, low quality); repeat FMT is suggested for recurrence within 8 weeks of an initial FMT (conditional, very low quality), restarting anti-CDI antibiotics to control symptoms before repeat FMT. For patients with recurrent CDI who are not FMT candidates, relapsed after FMT, or require ongoing or frequent courses of antibiotics, long-term suppressive oral vancomycin, ACG suggests 125 mg once daily, may be used (conditional, very low quality). Oral vancomycin prophylaxis 125 mg once daily may be considered during subsequent systemic antibiotic use in patients with a history of CDI at high risk of recurrence, typically continued until 5 days after completion of the systemic antibiotics (conditional, low quality). BEZLOTOXUMAB. Suggested for prevention of CDI recurrence in patients at high risk of recurrence (conditional recommendation, moderate quality), given as a single weight-based IV infusion (10 mg/kg) during a course of anti-CDI treatment. ACG explicitly narrows this: given the drug's cost and minimal benefit in low-risk patients, it recommends bezlotoxumab be considered for patients aged 65 years or older WHO ALSO HAVE at least one of the following additional risk factors, experiencing their second episode of CDI within the past 6 months, immunocompromised, or severe CDI. ACG does not recommend bezlotoxumab in patients with a history of heart failure and advises it be used with caution in patients with severe underlying cardiovascular comorbidities. ADJUNCTIVE. ACG recommends against probiotics for primary prevention of CDI in patients being treated with antibiotics (conditional, moderate quality) and against probiotics for prevention of CDI recurrence (strong recommendation, very low quality). ACG suggests against discontinuation of antisecretory therapy (e.g. PPI) in patients with CDI provided there is an appropriate indication for its use (strong recommendation, very low quality). SPECIAL POPULATIONS. Test for C. difficile in patients with IBD presenting with an acute flare associated with diarrhea (strong, low quality); treat IBD with CDI using vancomycin 125 mg four times daily for a minimum of 14 days (strong, very low quality); immunosuppressive IBD therapy should not be held during anti-CDI therapy, and escalation may be considered if there is no symptomatic improvement; FMT should be considered for recurrent CDI in IBD (strong, very low quality). Vancomycin is recommended for pregnant, peripartum, and breastfeeding patients. Vancomycin or fidaxomicin is suggested first line in immunocompromised patients. SCOPE LIMIT. ACG 2021 addresses C. difficile infection specifically; it makes no recommendation on the management of non-C. difficile antibiotic-associated diarrhea, and it predates the FDA approvals of Rebyota (Nov 2022) and Vowst (Apr 2023).

American College of Gastroenterology (Kelly CR, Fischer M, Allegretti JR, et al.), "ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections," American Journal of Gastroenterology, 2021 · reviewed 2026-07-20 ↗
de la Cuesta-Zuluaga J … Maier L · Nature Reviews Gastroenterology & Hepatology · IF 57.5 · PubMed ↗Permalink
← Back to issue №12 Every section of this issue is one click away, at the top of this page. Follow IBD by RSS